Work

Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer

Year: 2014

Type: article

Study design: Clinical Trial

Source: Investigational New Drugs

DOI: 10.1007/s10637-014-0088-3

Authors: Johanna C. Bendell, Heinz-Josef Lenz, Theresa Ryan, Bassel F. El-Rayes, John L. Marshall, Manuel R. Modiano, Lowell L. Hart, Clint D. Kingsley, Thomas J. George, Daisuke Nakashima, Jordan D. Berlin

Institutions: Sarah Cannon, Tennessee Oncology, University of Southern California, USC Norris Comprehensive Cancer Center, NYU Langone Health, New York University, Emory University, Winship Cancer Institute, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Arizona Oncology, Clearview Cancer Institute, University of Florida, Vanderbilt University, Vanderbilt-Ingram Cancer Center

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Kyowa Hakko Kirin

OpenAlex ID: W2044623920

FWCI: 0.603

Cites: 29

Cited by: 14

Related to: 10